Lung Cancer Clinical Trials in San Antonio

Showing 421-421 of 421 trials

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

NCT00062907

The purpose of this trial is to examine the safety and immunogenicity of a therapeutic vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients with early stage non-small cell lung cancer. The vaccine regimen will consist of two fixed doses of recombinant DNA (pVAX/L523S) followed by two doses of recombinant adenovirus (Ad/L523S). The trial will evaluate the dose escalation of Ad/L523S through three cohorts of patients.

Non-Small Cell Lung Cancer

Corixa Corporation9 participantsStarted May 2003

Ocoee, Florida, United States • Dallas, Texas, United States • Tyler, Texas, United States +2 more locations

PreviousPage 22 of 22

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Lung Cancer Trials in Other Cities

Other Conditions in San Antonio